BETOPTIC S
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BETOPTIC S (BETOPTIC S).
Betaxolol is a cardioselective beta-1 adrenergic receptor antagonist. In ophthalmic use, it reduces intraocular pressure by decreasing the production of aqueous humor, likely through blockade of beta-2 receptors in the ciliary epithelium.
| Metabolism | Primarily metabolized by CYP2D6 (hepatic). |
| Excretion | Renal: 0.3% unchanged; extensive hepatic metabolism to inactive metabolites; biliary/fecal elimination of metabolites accounts for the majority of excretion; total renal elimination of drug and metabolites is approximately 80%, with the remainder via feces. |
| Half-life | Terminal elimination half-life is approximately 4–6 hours in adults; prolonged in renal impairment and in elderly patients due to decreased clearance. |
| Protein binding | ~60% bound to plasma proteins (albumin). |
| Volume of Distribution | Large volume of distribution, estimated at 8–10 L/kg, indicating extensive tissue binding and distribution. |
| Bioavailability | Systemic bioavailability after ophthalmic administration is low, approximately 0.1–0.2% due to limited corneal penetration and nasolacrimal drainage. |
| Onset of Action | Ophthalmic: 30 minutes for intraocular pressure reduction; peak effect at 2 hours. |
| Duration of Action | Ophthalmic: 12 hours; can be administered twice daily for sustained effect. |
Instill 1 drop in the affected eye(s) twice daily.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No dose adjustment required. |
| Liver impairment | No dose adjustment required. |
| Pediatric use | Not established; safety and efficacy in children have not been studied. |
| Geriatric use | No specific dose adjustment; use caution due to potential systemic absorption and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BETOPTIC S (BETOPTIC S).
| Breastfeeding | Betaxolol is excreted in breast milk. The milk-to-plasma ratio is approximately 0.9 to 1.2 (mean 1.1). Infant dose is estimated at 0.1-0.5% of maternal weight-adjusted dose, which is below the 10% threshold for concern. However, monitor infant for bradycardia, hypotension, and hypoglycemia. Manufacturer advises caution. |
| Teratogenic Risk | Betaxolol is a selective beta1-adrenergic antagonist. In animal studies, no teratogenic effects were observed at doses up to 6 mg/kg/day (oral). However, beta-blockers may cause fetal bradycardia, growth restriction, and hypoglycemia. First trimester: limited human data, potential risk based on other beta-blockers. Second and third trimesters: risk of fetal bradycardia, intrauterine growth restriction, and neonatal beta-blockade effects (bradycardia, hypotension, hypoglycemia). Use only if benefit outweighs risk. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Absolute: Hypersensitivity to betaxolol or any component of the formulation; sinus bradycardia, second- or third-degree AV block, cardiogenic shock, overt heart failure.","Relative: Severe COPD or asthma (may exacerbate bronchospasm); diabetes mellitus (may mask hypoglycemia); thyrotoxicosis (may mask symptoms); history of severe anaphylaxis."]
| Precautions | ["Systemic absorption: May cause bronchospasm (use caution in asthma/COPD), bradycardia, heart block, hypotension; use with caution in patients with sinus node dysfunction, heart failure, or diabetes.","Ocular: Caution in patients with corneal epithelial defects; avoid in patients with history of severe anaphylactic reactions (beta-blockers may blunt response to epinephrine).","Masking of hypoglycemia symptoms (tachycardia) in diabetic patients.","Gradual withdrawal recommended if discontinuing after prolonged use."] |
| Food/Dietary | No significant food interactions. Avoid excessive alcohol which may lower intraocular pressure response or cause additional hypotension. |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and signs of bronchospasm. Fetal monitoring: nonstress test and biophysical profile as clinically indicated. Assess fetal growth via ultrasound. Neonatal monitoring: observe for bradycardia, hypoglycemia, and respiratory depression for 48-72 hours post-delivery. |
| Fertility Effects | No specific studies on human fertility. Beta-blockers may theoretically affect male reproductive function (reduced libido, erectile dysfunction). No known effect on female fertility. Animal studies do not indicate impairment of fertility at therapeutic doses. |
| Clinical Pearls | Betoptic S (betaxolol HCl) is a cardioselective beta-blocker used for lowering intraocular pressure in glaucoma. It may cause less bronchospasm than non-selective beta-blockers but still requires caution in asthma/COPD. Use with care in patients with bradycardia or heart block. Monitor for systemic beta-blockade effects (e.g., hypotension, bradycardia) especially in elderly or those with cardiovascular disease. Shake suspension well before use. Reduce frequency if used with oral beta-blockers. |
| Patient Advice | Shake the bottle vigorously for 10 seconds before each use. · Use exactly as prescribed; do not increase frequency. · If using other eye drops, wait at least 5-10 minutes between applications. · Avoid touching the dropper tip to any surface to prevent contamination. · Inform your doctor if you have asthma, COPD, heart problems, or diabetes. · May cause blurred vision temporarily; do not drive until vision clears. · Report symptoms like slow heart rate, breathing difficulty, or dizziness. |